Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
paper
Cited
Public
Unavailable
- Authors
- Ray, Lara A; Hutchison, Kent E
- Year
- 2007
- Journal
- Archives of general psychiatry
- PMID
- 17768272
- DOI
- 10.1001/archpsyc.64.9.1069
CONTEXT: Clinical trials have suggested a modest effect of naltrexone as a pharmacotherapy for alcoholism, and a recent study has suggested that the effects may be moderated by variations in the mu-opioid receptor gene (OPRM1). However, the mechanism by which naltrexone may be differentially effective as a function of the OPRM1 genotype is unclear. OBJECTIVES: (1) To replicate and expand on the association between the A118G single nucleotide polymorphism(SNP) of the OPRM1 gene and alcohol sensitivity, (2) to examine the effects of naltrexone on alcohol sensitivity, and (3) to test the A118G SNP of the OPRM1 gene as a moderator of the effects of naltrexone on alcohol sensitivity. DESIGN: A within-subject, double-blind, placebo-controlled laboratory trial of naltrexone. SETTING: Participants were recruited from the community. PARTICIPANTS: Non-treatment-seeking heavy drinkers were enrolled in the study. Prospective genotyping was conducted to oversample for the genetic variant of interest. Intervention After taking naltrexone (50 mg) or placebo, participants completed an intravenous alcohol challenge session in which they were assessed at baseline and at each of the 3 target breath alcohol concentrations: 0.02, 0.04, and 0.06 mg/L. MAIN OUTCOME MEASURES: The Biphasic Alcohol Effects Scale, the Alcohol Urge Questionnaire, the Profile of Mood States, and the Alcohol Rating Scale were administered. RESULTS: Individuals with at least 1 copy of the G allele reported lower alcohol craving and higher alcohol-induced "high" across rising breath alcohol concentrations. Naltrexone was found to blunt alcohol's effects on stimulation, positive mood, craving, and enjoyment. The effects of naltrexone on blunting alcohol-induced high were stronger among individuals with the G allele. CONCLUSION: This study advances the knowledge of mechanisms of action of naltrexone and genetic moderators of response to this pharmacotherapy.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Explaining increased efficacy of naltrexone in the treatment of alcohol dependent patients with a family history of alcohol use disorder: A systematic review on the role of reward sensitivity and sweet liking. | van Amsterdam J et al. | β | 2025 | β |
| Initial Subjective Response to Nicotine Vaping Predicts Subsequent E-Cigarette Use in Early Adolescence: An ABCD Investigation. | Courtney KE et al. | β | 2025 | β |
| Modern pharmacotherapy guidance for treating alcohol use disorders. | Soyka M et al. | β | 2025 | β |
| Alcohol and the dopamine system. | SΓΆderpalm B et al. | β | 2024 | β |
| EndpointsΒ for Pharmacotherapy Trials for AlcoholΒ Use Disorder. | Belnap MA et al. | β | 2024 | β |
| Substance Use Disorder. | Swimmer KR et al. | β | 2024 | β |
| Consuming oral cannabidiol prior to a standard alcohol dose has minimal effect on breath alcohol level and subjective effects of alcohol. | Karoly HC et al. | β | 2023 | β |
| Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention. | Volkow ND et al. | β | 2023 | β |
| The life and times of endogenous opioid peptides: Updated understanding of synthesis, spatiotemporal dynamics, and the clinical impact in alcohol use disorder. | Margolis EB et al. | β | 2023 | β |
| Translational models of addiction phenotypes to advance addiction pharmacotherapy. | Ray LA et al. | β | 2023 | β |
| Using naltrexone to validate a human laboratory test system to screen new medications for alcoholism (TESMA)- a randomized clinical trial. | Spreer M et al. | β | 2023 | β |
| Hazardous drinking and alcohol use disorders. | MacKillop J et al. | β | 2022 | β |
| Knock-In Mouse Models to Investigate the Functions of Opioid Receptors <i>in vivo</i>. | Degrandmaison J et al. | β | 2022 | β |
| Mu opioid receptor gene variant modulates subjective response to smoked cannabis. | Bourgault Z et al. | β | 2022 | β |
| Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder. | Burnette EM et al. | β | 2022 | β |
| Pharmacogenetics of Addiction Therapy. | Graham DP et al. | β | 2022 | β |
| Within- and between-person effects of naltrexone on the subjective response to alcohol and craving: A daily diary investigation. | Waddell JT et al. | β | 2022 | β |
| Clinical Neuroscience of Addiction: What Clinical Psychologists Need to Know and Why. | Ray LA et al. | β | 2021 | β |
| A novel human laboratory model for screening medications for alcohol use disorder. | Ho D et al. | β | 2020 | β |
| Differential sensitivity of human neurons carrying ΞΌ opioid receptor (MOR) N40D variants in response to ethanol. | Scarnati MS et al. | β | 2020 | β |
| Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial. | Anton RF et al. | β | 2020 | β |
| Pharmacotherapies and personalized medicine for alcohol use disorder: a review. | Lohoff FW | β | 2020 | β |
| Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. | Hartwell EE et al. | β | 2020 | β |
| The ΞΌ-opioid receptor gene A118G polymorphism is associated with insecure attachment in children with disruptive mood regulation disorder and their mothers. | Cimino S et al. | β | 2020 | β |
| Advancing Precision Medicine for Alcohol Use Disorder: Replication and Extension of Reward Drinking as a Predictor of Naltrexone Response. | Witkiewitz K et al. | β | 2019 | β |
| Lack of Association between Opioid-Receptor Genotypes and Smoking Cessation Outcomes in a Randomized, Controlled Naltrexone Trial. | Roche DJO et al. | β | 2019 | β |
| Mobile alcohol biosensors and pharmacotherapy development research. | Roberts W et al. | β | 2019 | β |
| Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders. | Burns JA et al. | β | 2019 | β |
| Naltrexone effects on subjective responses to alcohol in the human laboratory: A systematic review and meta-analysis. | Ray LA et al. | β | 2019 | β |
| Pharmacogenetics of alcohol use disorder treatments: an update. | Hartwell EE et al. | β | 2019 | β |
| Precision psychiatry-What it means for eating disorders? | Kan C et al. | β | 2019 | β |
| Reward, Relief and Habit Drinking: Initial Validation of a Brief Assessment Tool. | Grodin EN et al. | β | 2019 | β |
| State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. | Ray LA et al. | β | 2019 | β |
| The influence of the OPRM1 (A118G) polymorphism on behavioral and neural correlates of aggression in healthy males. | Weidler C et al. | β | 2019 | β |
| Application of Research Domain Criteria to childhood and adolescent impulsive and addictive disorders: Implications for treatment. | Yip SW et al. | β | 2018 | β |
| Characterization of hangover following intravenous alcohol exposure in social drinkers: methodological and clinical implications. | Vatsalya V et al. | β | 2018 | β |
| Cost-Effectiveness Analysis of Genotype-Guided Treatment Allocation in Patients with Alcohol Use Disorders Using Naltrexone or Acamprosate, Using a Modeling Approach. | Sluiter RL et al. | β | 2018 | β |
| Distress Tolerance and Craving for Cigarettes Among Heavy Drinking Smokers. | Lim AC et al. | β | 2018 | β |
| Heroin-induced suppression of saccharin intake in OPRM1 A118G mice. | Freet CS et al. | β | 2018 | β |
| Increased ethanol drinking in "humanized" mice expressing the mu opioid receptor A118G polymorphism are mediated through sex-specific mechanisms. | Henderson-Redmond AN et al. | β | 2018 | β |
| Naltrexone alters alcohol self-administration behaviors and hypothalamic-pituitary-adrenal axis activity in a sex-dependent manner in rats. | Nieto SJ et al. | β | 2018 | β |
| New steps for treating alcohol use disorder. | Campbell EJ et al. | β | 2018 | β |
| Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial. | Ray LA et al. | β | 2018 | β |
| Relationship between tonic and phasic craving for alcohol. | Hartwell EE et al. | β | 2018 | β |
| The role of the orbitofrontal cortex in alcohol use, abuse, and dependence. | Moorman DE | β | 2018 | β |
| A prospective study of genetic factors, human laboratory phenotypes, and heavy drinking in late adolescence. | Hendershot CS et al. | β | 2017 | β |
| Effects of naltrexone on alcohol self-administration and craving: meta-analysis of human laboratory studies. | Hendershot CS et al. | β | 2017 | β |
| Endogenous opioid system: a promising target for future smoking cessation medications. | Norman H et al. | β | 2017 | β |
| Functional significance of subjective response to alcohol across levels of alcohol exposure. | Bujarski S et al. | β | 2017 | β |
| Impulsivity Moderates Subjective Responses to Alcohol in Alcohol-Dependent Individuals. | Westman JG et al. | β | 2017 | β |
| Independent and Interactive Effects of OPRM1 and DAT1 Polymorphisms on Alcohol Consumption and Subjective Responses in Social Drinkers. | Weerts EM et al. | β | 2017 | β |
| Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study. | Quelch DR et al. | β | 2017 | β |
| Promising pharmacogenetic targets for treating alcohol use disorder: evidence from preclinical models. | Rinker JA et al. | β | 2017 | β |
| Alcohol addiction and the mu-opioid receptor. | Berrettini W | β | 2016 | β |
| A Prospective 5-Year Re-examination of Alcohol Response in Heavy Drinkers Progressing in Alcohol Use Disorder. | King AC et al. | β | 2016 | β |
| Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. | Schwantes-An TH et al. | β | 2016 | β |
| Associations of OPRM1 A118G and alcohol sensitivity with intravenous alcohol self-administration in young adults. | Hendershot CS et al. | β | 2016 | β |
| Experimental psychopathology paradigms for alcohol use disorders: Applications for translational research. | Bujarski S et al. | β | 2016 | β |
| Opioid Antagonists and the A118G Polymorphism in the ΞΌ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype. | Ziauddeen H et al. | β | 2016 | β |
| Opioid neuroscience for addiction medicine: From animal models to FDA approval for alcohol addiction. | Berrettini W | β | 2016 | β |
| Prefrontal Cortical Opioids and Dysregulated Motivation: A Network Hypothesis. | Baldo BA | β | 2016 | β |
| Primary Care Providers' Interest in Using a Genetic Test to Guide Alcohol Use Disorder Treatment. | Williams EC et al. | β | 2016 | β |
| The Effects of Pharmacological Opioid Blockade on Neural Measures of Drug Cue-Reactivity in Humans. | Courtney KE et al. | β | 2016 | β |
| What does addiction medicine expect from neuroscience? From genes and neurons to treatment responses. | Le Foll B | β | 2016 | β |
| Alcohol Consumption in Healthy OPRM1 G Allele Carriers and Its Association with Impulsive Behavior. | Pfeifer P et al. | β | 2015 | β |
| An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate. | Gueorguieva R et al. | β | 2015 | β |
| A pharmacogenetic determinant of mu-opioid receptor antagonist effects on alcohol reward and consumption: evidence from humanized mice. | Bilbao A et al. | β | 2015 | β |
| A pilot trial of prazosin, an alpha-1 adrenergic antagonist, for comorbid alcohol dependence and posttraumatic stress disorder. | Simpson TL et al. | β | 2015 | β |
| Cocaine-induced suppression of saccharin intake and morphine modulation of CaΒ²βΊ channel currents in sensory neurons of OPRM1 A118G mice. | Freet CS et al. | β | 2015 | β |
| Common single nucleotide variants underlying drug addiction: more than a decade of research. | BΓΌhler KM et al. | β | 2015 | β |
| Complexities of the mu opioid receptor. | Berrettini W | β | 2015 | β |
| KCNN Genes that Encode Small-Conductance Ca2+-Activated K+ Channels Influence Alcohol and Drug Addiction. | Padula AE et al. | β | 2015 | β |
| Mouse model of OPRM1 (A118G) polymorphism has altered hippocampal function. | Mague SD et al. | β | 2015 | β |
| OPRM1 genotype and naltrexone response in depressed alcohol-dependent patients. | Foulds JA et al. | β | 2015 | β |
| Social network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study. | Worley MJ et al. | β | 2015 | β |
| Subjective response as a consideration in the pharmacogenetics of alcoholism treatment. | Roche DJ et al. | β | 2015 | β |
| The role of opioidergic genes in the treatment outcome of drug addiction pharmacotherapy: A systematic review. | Bauer IE et al. | β | 2015 | β |
| Effects of naltrexone on adolescent alcohol cue reactivity and sensitivity: an initial randomized trial. | Miranda R et al. | β | 2014 | β |
| Future pharmacological treatments for substance use disorders. | Forray A et al. | β | 2014 | β |
| Genetic influences on response to alcohol and response to pharmacotherapies for alcoholism. | Enoch MA | β | 2014 | β |
| Interactive effects of OPRM1 and DAT1 genetic variation on subjective responses to alcohol. | Ray LA et al. | β | 2014 | β |
| Molecular and neurologic responses to chronic alcohol use. | Costin BN et al. | β | 2014 | β |
| Neurochemical mechanisms of alcohol withdrawal. | Becker HC et al. | β | 2014 | β |
| Opportunities for the development of neuroimmune therapies in addiction. | Ray LA et al. | β | 2014 | β |
| Pharmacogenetic approaches in the treatment of alcohol use disorders: addressing clinical utility and implementation thresholds. | Hendershot CS | β | 2014 | β |
| Pharmacogenetics of addiction therapy. | Nielsen DA et al. | β | 2014 | β |
| Pharmacogenetics of OPRM1. | Crist RC et al. | β | 2014 | β |
| Pharmacological approaches to reducing craving in patients with alcohol use disorders. | Haass-Koffler CL et al. | β | 2014 | β |
| Pharmacologic treatment of alcoholism. | Anton RF et al. | β | 2014 | β |
| Reduction of the reinforcing effectiveness of cocaine by continuous D-amphetamine treatment in rats: importance of active self-administration during treatment period. | Zimmer BA et al. | β | 2014 | β |
| Subjective responses to alcohol in the lab predict neural responses to alcohol cues. | Courtney KE et al. | β | 2014 | β |
| The behavioral economics of substance use disorders: reinforcement pathologies and their repair. | Bickel WK et al. | β | 2014 | β |
| Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings. | Ray LA et al. | β | 2014 | β |
| Cravings as a mediator and moderator of drinking outcomes in the COMBINE study. | Subbaraman MS et al. | β | 2013 | β |
| Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: a bold FMRI study. | Lukas SE et al. | β | 2013 | β |
| Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. | Schacht JP et al. | β | 2013 | β |
| Modeling alcohol use disorder severity: an integrative structural equation modeling approach. | Moallem NR et al. | β | 2013 | β |
| Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade? | Sullivan MA et al. | β | 2013 | β |
| Opioidergic and dopaminergic manipulation of gambling tendencies: a preliminary study in male recreational gamblers. | Porchet RI et al. | β | 2013 | β |
| Opioid pharmacogenetics of alcohol addiction. | Berrettini W | β | 2013 | β |
| Peter Riederer "70th birthday" neurobiological foundations of modern addiction treatment. | Jacob C | β | 2013 | β |
| Subjective response to alcohol among alcohol-dependent individuals: effects of the ΞΌ-opioid receptor (OPRM1) gene and alcoholism severity. | Ray LA et al. | β | 2013 | β |
| The effects of varenicline on stress-induced and cue-induced craving for cigarettes. | Ray LA et al. | β | 2013 | β |
| The ΞΌ-opioid receptor and treatment response to naltrexone. | Thorsell A | β | 2013 | β |
| Variation in Mu-Opioid Receptor Gene <i>(OPRM1)</i> as a Moderator of Naltrexone Treatment to Reduce Heavy Drinking in a High Functioning Cohort. | Chen AC et al. | β | 2013 | β |
| Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment. | Kranzler HR et al. | β | 2013 | β |
| Ξ²-Arrestin 2 knockout mice exhibit sensitized dopamine release and increased reward in response to a low dose of alcohol. | BjΓΆrk K et al. | β | 2013 | β |
| Alcohol consumption induces endogenous opioid release in the human orbitofrontal cortex and nucleus accumbens. | Mitchell JM et al. | β | 2012 | β |
| Alternative substance paradigm: effectiveness of beverage blinding and effects on acute alcohol responses. | Conrad M et al. | β | 2012 | β |
| A prospective study of stress and alcohol craving in heavy drinkers. | Tartter MA et al. | β | 2012 | β |
| Association of Β΅-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. | Chamorro AJ et al. | β | 2012 | β |
| Close association between A118G single nucleotide polymorphism and opioid, alcohol, and nicotine dependence. | Kapoor S | β | 2012 | β |
| Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol. | Ashenhurst JR et al. | β | 2012 | β |
| Direct-to-consumer genetic testing for addiction susceptibility: a premature commercialisation of doubtful validity and value. | Mathews R et al. | β | 2012 | β |
| Human laboratory paradigms in alcohol research. | Plebani JG et al. | β | 2012 | β |
| Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone. | Setiawan E et al. | β | 2012 | β |
| Medications development to treat alcohol dependence: a vision for the next decade. | Litten RZ et al. | β | 2012 | β |
| Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes. | Anton RF et al. | β | 2012 | β |
| OPRM1 and diagnosis-related posttraumatic stress disorder in binge-drinking patients living with HIV. | Nugent NR et al. | β | 2012 | β |
| Personalized treatment of alcohol dependence. | Kranzler HR et al. | β | 2012 | β |
| Pharmacogenetics of alcoholism: a clinical neuroscience perspective. | Ray LA et al. | β | 2012 | β |
| Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study. | Ray LA et al. | β | 2012 | β |
| Reduced expression of the ΞΌ opioid receptor in some, but not all, brain regions in mice with OPRM1 A112G. | Wang YJ et al. | β | 2012 | β |
| The genetics of addiction-a translational perspective. | Agrawal A et al. | β | 2012 | β |
| The genetics of the opioid system and specific drug addictions. | Levran O et al. | β | 2012 | β |
| The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review. | Ray LA et al. | β | 2012 | β |
| Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study. | Bujarski S et al. | β | 2012 | β |
| Using genetically engineered animal models in the postgenomic era to understand gene function in alcoholism. | Reilly MT et al. | β | 2012 | β |
| A genetic determinant of the striatal dopamine response to alcohol in men. | Ramchandani VA et al. | β | 2011 | β |
| Child ΞΌ-opioid receptor gene variant influences parent-child relations. | Copeland WE et al. | β | 2011 | β |
| Examining naltrexone and alcohol effects in a minority population: results from an initial human laboratory study. | Plebani JG et al. | β | 2011 | β |
| Genetics of alcohol dependence. | Kimura M et al. | β | 2011 | β |
| Naloxone blocks ethanol-mediated appetitive conditioning and locomotor activation in adolescent rats. | Pautassi RM et al. | β | 2011 | β |
| Opiate-induced dopamine release is modulated by severity of alcohol dependence: an [(18)F]fallypride positron emission tomography study. | Spreckelmeyer KN et al. | β | 2011 | β |
| Opioid modulators for alcohol dependence. | Hillemacher T et al. | β | 2011 | β |
| Pharmacogenetic approaches to the treatment of alcohol addiction. | Heilig M et al. | β | 2011 | β |
| Pharmacogenetics of alcohol, nicotine and drug addiction treatments. | Sturgess JE et al. | β | 2011 | β |
| Pharmacogenomics of the human Β΅-opioid receptor. | Kasai S et al. | β | 2011 | β |
| Pilot study examining the frequency of several gene polymorphisms involved in morphine pharmacodynamics and pharmacokinetics in a morbidly obese population. | Lloret Linares C et al. | β | 2011 | β |
| Stress-induced and cue-induced craving for alcohol in heavy drinkers: Preliminary evidence of genetic moderation by the OPRM1 and CRH-BP genes. | Ray LA | β | 2011 | β |
| The effect of naltrexone on alcohol's stimulant properties and self-administration behavior in social drinkers: influence of gender and genotype. | Setiawan E et al. | β | 2011 | β |
| Antagonist-agonist combinations as therapies for heroin addiction: back to the future? | Nutt DJ | β | 2010 | β |
| A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys. | Vallender EJ et al. | β | 2010 | β |
| ChIP-chip analysis of neurexins and other candidate genes for addiction and neuropsychiatric disorders. | Pedrosa E et al. | β | 2010 | β |
| Consilient research approaches in studying gene x environment interactions in alcohol research. | Sher KJ et al. | β | 2010 | β |
| Covariates of craving in actively drinking alcoholics. | Chakravorty S et al. | β | 2010 | β |
| Initial evidence of an association between OPRM1 and adolescent alcohol misuse. | Miranda R et al. | β | 2010 | β |
| Naltrexone selectively elevates GABAergic neuroactive steroid levels in heavy drinkers with the Asp40 allele of the OPRM1 gene: a pilot investigation. | Ray LA et al. | β | 2010 | β |
| Neural markers of genetic vulnerability to drug addiction. | MΓΌller DJ et al. | β | 2010 | β |
| New horizons for therapeutics in drug and alcohol abuse. | Jupp B et al. | β | 2010 | β |
| Opioid antagonists for alcohol dependence. | RΓΆsner S et al. | β | 2010 | β |
| OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. | Mague SD et al. | β | 2010 | β |
| Pharmacogenetics of alcohol and alcohol dependence treatment. | Kranzler HR et al. | β | 2010 | β |
| Polymorphisms of the mu-opioid receptor and dopamine D4 receptor genes and subjective responses to alcohol in the natural environment. | Ray LA et al. | β | 2010 | β |
| Quetiapine for the treatment of alcoholism: scientific rationale and review of the literature. | Ray LA et al. | β | 2010 | β |
| Subjective responses to alcohol consumption as endophenotypes: advancing behavioral genetics in etiological and treatment models of alcoholism. | Ray LA et al. | β | 2010 | β |
| Substance use disorders: realizing the promise of pharmacogenomics and personalized medicine. | Hutchison KE | β | 2010 | β |
| Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus. | Barr CS et al. | β | 2010 | β |
| The Effects of Naltrexone Among Alcohol Non-Abstainers: Results from the COMBINE Study. | Ray LA et al. | β | 2010 | β |
| Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues. | Heilig M et al. | β | 2010 | β |
| Acamprosate and naltrexone treatment effects on ethanol and sucrose seeking and intake in ethanol-dependent and nondependent rats. | Czachowski CL et al. | β | 2009 | β |
| Alcoholism: a systems approach from molecular physiology to addictive behavior. | Spanagel R | β | 2009 | β |
| A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. | Kim SG et al. | β | 2009 | β |
| A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. | Simpson TL et al. | β | 2009 | β |
| A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. | Ray LA et al. | β | 2009 | β |
| A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence. | Brown ES et al. | β | 2009 | β |
| Associations among GABRG1, level of response to alcohol, and drinking behaviors. | Ray LA et al. | β | 2009 | β |
| Catching the alcohol buzz: an examination of the latent factor structure of subjective intoxication. | Ray LA et al. | β | 2009 | β |
| Effects of alcoholism typology on response to naltrexone in the COMBINE study. | Bogenschutz MP et al. | β | 2009 | β |
| Effects of naltrexone on cortisol levels in heavy drinkers. | Ray LA et al. | β | 2009 | β |
| Expanding the utility of the Biphasic Alcohol Effects Scale (BAES) and initial psychometric support for the Brief-BAES (B-BAES). | Rueger SY et al. | β | 2009 | β |
| Food addiction in humans. | Pelchat ML | β | 2009 | β |
| From taste hedonics to motivational drive: central ΞΌ-opioid receptors and binge-eating behaviour. | Nathan PJ et al. | β | 2009 | β |
| Genetics of alcohol dependence. | Gelernter J et al. | β | 2009 | β |
| Identifying the neural circuitry of alcohol craving and relapse vulnerability. | Heinz A et al. | β | 2009 | β |
| Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. | Mague SD et al. | β | 2009 | β |
| Naltrexone aversion and treatment efficacy are greatest in humans and rats that actively consume high levels of alcohol. | Mitchell JM et al. | β | 2009 | β |
| Naltrexone for the treatment of alcohol dependence among African Americans: results from the COMBINE Study. | Ray LA et al. | β | 2009 | β |
| Now or Later? An fMRI study of the effects of endogenous opioid blockade on a decision-making network. | Boettiger CA et al. | β | 2009 | β |
| Relatively strong automatic appetitive action-tendencies in male carriers of the OPRM1 G-allele. | Wiers RW et al. | β | 2009 | β |
| The genetics of alcoholism. | Stacey D et al. | β | 2009 | β |
| The potential of pharmacogenomics to treat drug addiction. | Haile CN et al. | β | 2009 | β |
| Young Investigator Award symposium. | Witkiewitz K et al. | β | 2009 | β |
| Addiction: the clinical interface. | Nutt D et al. | β | 2008 | β |
| Association between single nucleotide polymorphisms in the mu opioid receptor gene (OPRM1) and self-reported responses to alcohol in American Indians. | Ehlers CL et al. | β | 2008 | β |
| Differential neural response to alcohol priming and alcohol taste cues is associated with DRD4 VNTR and OPRM1 genotypes. | Filbey FM et al. | β | 2008 | β |
| Effects of naltrexone during the descending limb of the blood alcohol curve. | Ray LA et al. | β | 2008 | β |
| Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. | Miranda R et al. | β | 2008 | β |
| Endogenous opiates and behavior: 2007. | Bodnar RJ | β | 2008 | β |
| Matching clients to psychosocial treatments: at the cusp of hope and evidence? | Finney JW | β | 2008 | β |
| Naltrexone in the treatment of alcohol dependence. | Unterwald EM | β | 2008 | β |
| Pharmacogenetic treatments for drug addiction: alcohol and opiates. | Haile CN et al. | β | 2008 | β |
| Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. | Grant JE et al. | β | 2008 | β |
| Preserved DNA from past clinical trials yields new information about a subtype of alcoholism. | O'Brien CP | β | 2008 | β |
| Review. Evidence-based treatments of addiction. | O'Brien CP | β | 2008 | β |
| The incentive salience of alcohol: translating the effects of genetic variant in CNR1. | Hutchison KE et al. | β | 2008 | β |
| Variation at the mu-opioid receptor gene (OPRM1) influences attachment behavior in infant primates. | Barr CS et al. | β | 2008 | β |
| Pharmacological effects of naltrexone and intravenous alcohol on craving for cigarettes among light smokers: a pilot study. | Ray LA et al. | β | 2007 | β |
| Toward a rational selection of treatment for addiction. | O'Brien CP | β | 2007 | β |
| Treatment of addiction in the era of genomic medicine. | O'Brien C | β | 2007 | β |